Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
Robert LaingJennifer UribeSantiago Uribe-LewisJulian Money-KyrleCarla PernaStylianos ChintzoglouSara KhaksarStephen E M LangleyPublished in: BJU international (2018)
LDR-PB is effective at controlling localised prostate cancer in patients with a high risk of disease relapse. As the present study was not randomised, it is not possible to define those patients who need the addition of ADT and/or EBRT. However, the NICE criteria appear suitable to define treatment options where patients could benefit from LDR-PB as monotherapy or combined treatment. This choice should be discussed with the patient taking into account comorbidities and presence of multiple high-risk factors.
Keyphrases
- prostate cancer
- low dose
- risk factors
- high dose
- radical prostatectomy
- clinical trial
- end stage renal disease
- heavy metals
- combination therapy
- ejection fraction
- radiation therapy
- chronic kidney disease
- open label
- squamous cell carcinoma
- case report
- locally advanced
- risk assessment
- double blind
- patient reported
- placebo controlled